Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


University of Auckland welcomes rheumatic fever initiative

The University of Auckland

18 February 2013

University of Auckland welcomes rheumatic fever initiative

The University of Auckland has welcomed an announcement by the New Zealand and Australian Prime Ministers of funding to investigate potential vaccines against rheumatic fever.

The prime ministers have committed NZ$3 million over two years for a trans-Tasman project to identify vaccines that could be taken into clinical development.

Rheumatic fever can cause life-threatening rheumatic heart disease. The disease is now rare in most wealthy countries, but remains a major health concern in New Zealand and Australia. Māori, Pasifika and Aboriginal communities in particular have amongst the highest rates of rheumatic heart disease in the world.

Rheumatic fever is the result of an immune reaction to infection by group A streptococcus, and vaccination against the bacterium has the potential to prevent the disease. There are many different strains of group A streptococcus worldwide, and the vaccine project will focus on those found in New Zealand and Australia.

The vaccine project complements ongoing public health programs that address the issues which contribute to high rates of the disease in New Zealand and Australia.

“The University has considerable expertise in both the basic science of group A streptococcus infection and the public health approaches required to tackle high rates of rheumatic fever. We’re delighted to have been actively engaged in investigating potential vaccine candidates,” says Professor John Fraser, Dean of the Faculty of Medical and Health Sciences, who is a world expert in streptococcal pathogenesis.

Professor Fraser says that the University looks forward to the release of further details on the project.

ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Royal Society: Review Finds Community Water Fluoridation Safe And Effective

A review of the scientific evidence for and against the efficacy and safety of fluoridation of public water supplies has found that the levels of fluoridation used in New Zealand create no health risks and provide protection against tooth decay. More>>

ALSO:

Scoop Business: Croxley Calls Time On NZ Production In Face Of Cheap Imports

Croxley Stationery, whose stationery brands include Olympic, Warwick and Collins, plans to cease manufacturing in New Zealand because it has struggled to compete with lower-cost imports in a market where the printed word is giving way to electronic communications. More>>

ALSO:

Prefu Roundup: Forecasts Revised, Surplus Intact

The National government heads into the election with its Budget surplus target broadly intact, delivering a set of economic and fiscal forecasts marginally revised from May to reflect weaker commodity prices and a lower tax take. More>>

ALSO:

Convention Centre: Major New SkyCity Hotel And Laneway For Auckland

Today SKYCITY Entertainment Group Limited revealed plans to build a new hotel and pedestrian laneway of bars, restaurants and boutique shopping on land it owns in the Nelson and Hobson Streets block, expanding the SKYCITY Entertainment Precinct. More>>

ALSO:

Igniting The Spark: Bringing The Digital Enabler To Life

Changing a name is, relatively speaking, the easy part of a re-invention. Changing a culture, getting all the ducks in a row, turning yourself inside-out to become customer-inspired is a much bigger challenge. More>>

ALSO:

Ebola And NZ: Targeted Screening At Airport But Risk Low

The risk of any cases of Ebola in New Zealand remains very low, but health and border authorities are well prepared... anyone arriving in New Zealand who in the last three weeks has visited countries affected will be screened for symptoms of the disease. More>>

ALSO:

Scoop Business: Brewer Seeking Crowd-Funding Cancels Shareholders’ Dividends

Shareholders in Renaissance Brewing company, the first business to seek equity through crowd-funding in New Zealand, have cancelled their claim on $147,000 of accumulated earnings “to make Renaissance a more attractive investment opportunity.” More>>

ALSO:

Get More From Scoop

 
 
Computer Power Plus

Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news